Mar 2, 2026 06:01AM FDA accepts rusfertide application with priority review for blood disorder

Feb 10, 2026 04:50AM FDA accepts Takeda drug application for narcolepsy treatment

Jan 22, 2026 07:45AM Takeda launches GAMMAGARD LIQUID ERC immunoglobulin therapy in US

Jan 15, 2026 07:52AM Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY5,600 at BofA Securities

Jan 13, 2026 07:47AM Morgan Stanley Resumes Takeda Pharmaceutical (4502:JP) (TAK) at Overweight, 'Our second most preferred stock'

Jan 5, 2026 07:03AM Takeda and Protagonist submit drug application for polycythemia vera treatment

Dec 8, 2025 02:54AM Protagonist and Takeda report 52-week rusfertide data in polycythemia vera

Nov 7, 2025 11:01AM Takeda reports sustained kidney function benefits 18 months after treatment

Nov 5, 2025 08:03AM Truist Securities Comments on Centessa Pharmaceuticals (CNTA) Amid 18pct Drop

Oct 30, 2025 04:11AM Takeda Pharmaceutical Company Limited (TAK) Reports Q3 EPS of JPY279.00

Sep 19, 2025 09:14AM Raymond James: 'LinkedIn posts from executives at AbbVie indicate that the company has selected Salesforce for its future CRM'

Sep 16, 2025 08:02AM Takeda partners with VELA for wind-powered pharmaceutical shipping

Aug 21, 2025 02:53PM Takeda (TAK) 1400 contracts of September 17.50 calls trade, share price down 1%

Aug 8, 2025 01:18AM Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis

Jul 30, 2025 05:14PM Takeda Pharmaceutical Company Limited (TAK) Reports Q2 EPS of JPY151.00

Jul 21, 2025 08:01AM Takeda receives FDA clearance for HYQVIA administration devices

Jul 14, 2025 05:55AM Takeda reports positive phase 3 results for narcolepsy type 1 drug

Jun 3, 2025 10:13AM Takeda (TAK) announces EC approval of ADCETRIS

May 21, 2025 09:32AM TD Cowen Reiterates Buy Rating on Takeda Pharmaceutical (TAK) Ahead of 'Key Upcoming Readouts'

May 14, 2025 05:10PM Takeda (TAK) announces publication of data from Phase 2b trial of Tak-861

Apr 2, 2025 04:50AM Morgan Stanley Upgrades Takeda Pharmaceutical (4502:JP) (TAK) to Overweight

Mar 3, 2025 06:46AM Protagonist Therapeutics (PTGX) and Takeda (TAK) Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Jan 21, 2025 08:03AM Keros Therapeutics (KROS) Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

Jan 7, 2025 11:00AM TD Cowen on Pharma: '10 Events in 2025 That Could Change Practice, Alter Companies, Move Stocks'

Dec 3, 2024 07:00AM Keros Therapeutics (KROS) Announces Global License Agreement with Takeda to Advance Elritercept

Aug 7, 2024 06:45AM Takeda (TAK) Receives EU Approval for ADZYNMA

Jun 26, 2024 05:27AM Takeda (TAK) Announces Board Changes

Jun 21, 2024 04:00PM Takeda (TAK) Receives EU Approval for FRUZAQLA

Jun 18, 2024 08:02AM Takeda (TAK) Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA

Jun 17, 2024 06:45AM Takeda (TAK) Reports Phase 3 Topline Results for Soticlestat